A Phase Ia/Ib Study of IBI315 in Patients With HER2-expressing Advanced Solid Tumor

• Status: Recruiting
• Trial end date: 2025-12-30
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this phase I study is to evaluate the safety and potential efficacy and to determine the recommended phase 2 dose (RP2D) of IBI315, a HER2/PD-1 bi-specific antibody in patients with advanced solid tumors

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Criteria

Inclusion Criteria:

• Written (signed) informed consent.

• Life expectancy ≥12 weeks.

• Patients with HER2-expressing advanced solid tumor who failed on current standard of care

• According to RECIST 1.1, at least one measurable lesion (radiation-naïve) exists.

• ECOG performance status 0-1.

• Adequate organ and marrow function evaluated by laboratory tests as follow:

• CBC: absolute neutrophil count (ANC) ≥ 1.0×109/L (Ia stage) or 1.5×109/L (Ib stage); Platelet (PLT) ≥ 75×109/L; Hemoglobin (HGB) ≥ 9.0g/L;

• Liver function: Total bilirubin (TBIL) ≤ 1.5×upper limit of normal value (ULN) for patients without hepatic metastases, ≤ 2×ULN for patients with hepatic metastases or Gilbert syndrome; Alanine aminotransferase (ALT) ≤ 2.5×ULN; Aspartate transferase (AST) ≤ 2.5×ULN;

• Renal function: Clearance of creatinine (CCr) by Cockcroft-Gault formula or 24-hour urine collection ≥ 50ml/min;

• Urinalysis: urine protein < 2+ or urine protein in 24-hour urine collection < 1g;

• Coagulation function: activated partial thromboplastin time (APTT）≤ 1.5×ULN; international normalized ratio (INR）≤ 1.5

• left ventricular ejection fraction (LVEF) ≥ 50% by echocardiography;

• Accumulative exposure to doxorubicin ≤ 360mg/m2; accumulative exposure to epirubicin ≤ 720mg/m2;

• Agree to use an approved contraceptive method during the treatment period, until 180 days after last dose of treatment.

• Post-menopause female subject or pre-menopause female with negative HCG level in urine or blood.

Exclusion Criteria:

• Any greater than NCI CTCAE 0/1 adverse event exists within 4 weeks before enrollment, not including hair loss and fatigue;

• Received major surgery or having unhealed wound, ulcer, or bone fracture;• Received whole pelvic radiation;

• Plan to receive any other anti-cancer therapy not specified in the protocol, except for palliative radiotherapy;

• CNS metastasis, spinal compression, or carcinomatous meningitis

• Active autoimmune disease or inflammatory disorders.

• Primary immunodeficiency diseases;

• Pregnant or breast-feeding female.